ClinConnect ClinConnect Logo
Search / Trial NCT05057143

3D Printed Implants for the Defect Reconstruction in Patients With Chest Wall Tumors

Launched by BLOKHIN'S RUSSIAN CANCER RESEARCH CENTER · Sep 15, 2021

Trial Information

Current as of July 01, 2025

Recruiting

Keywords

Chest Wall Tumor Surgery

ClinConnect Summary

This clinical trial is exploring the use of 3D printed titanium implants to help reconstruct the chest wall in patients who have tumors in that area. The goal is to create personalized implants that fit perfectly into the space left after removing the tumor. This process starts with a detailed CT scan, followed by the creation of a model that matches the patient's unique anatomy. Using advanced 3D printing technology, researchers aim to improve the surgical outcome by making sure the implant closely resembles the original shape of the chest wall, which can help reduce complications and speed up recovery.

To participate in this trial, individuals must be adults aged 65 and older who have specific types of tumors affecting the ribs, sternum, or clavicle, including both malignant (cancerous) and benign (non-cancerous) tumors. They should not have distant metastases (cancer spread to other parts of the body) and must be able to give informed consent. If eligible, participants can expect to undergo a surgical procedure with a recovery period of 15 to 30 days. This innovative approach not only aims to improve physical outcomes but also enhances the overall quality of life for patients facing chest wall tumors.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Malignant neoplasm of ribs, sternum and clavicle
  • Malignant neoplasm of the connective and soft tissues of the chest
  • Neoplasm of uncertain or unknown nature of ribs, sternum and collarbone
  • Benign neoplasm of ribs, sternum and collarbone
  • Tumor lesions of the chest wall of any localization, malignant and benign, as well as of an uncertain or unknown nature
  • For malignant tumors: Grade 1-3
  • Lack of distant metastases
  • Signed informed consent
  • Exclusion Criteria:
  • Children, women during pregnancy, childbirth, women during breastfeeding.
  • Military personnel, with the exception of contract military personnel.
  • Persons with mental disorders.
  • Persons detained, taken into custody, serving a sentence in the form of restriction of freedom, arrest, imprisonment or administrative arrest.
  • Patients with distant metastases (except for a solitary focus in the chest wall without other manifestations of the disease)
  • Inoperable tumor
  • The presence of another malignant tumor at the time of examination
  • ECOG 4
  • Having an active or chronic fungal / bacterial / viral infection
  • Uncontrolled chronic diseases of the liver, kidneys in the acute stage
  • Presence of metastases

About Blokhin's Russian Cancer Research Center

Blokhin's Russian Cancer Research Center is a leading institution dedicated to advancing cancer research and treatment in Russia and beyond. Established with a focus on innovative oncology solutions, the center integrates cutting-edge scientific inquiry with clinical application, aiming to improve patient outcomes through novel therapeutic approaches. With a multidisciplinary team of experts, the center fosters collaboration in the fields of clinical trials, epidemiology, and molecular biology, contributing significantly to the global fight against cancer. Its commitment to excellence in research and patient care positions Blokhin's Russian Cancer Research Center at the forefront of oncology advancements.

Locations

Moscow, , Russian Federation

Patients applied

0 patients applied

Trial Officials

Aslan Valiev, PhD

Principal Investigator

N.N. Blokhin NMRCO

Pavel Kononets, PhD

Principal Investigator

N.N. Blokhin NMRCO

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials